Publications

October 01, 2018
Nature Genetics

CTD2 scientists at DFCI systematically analyzed loss-of-function screens in cancer cell lines combined with TP53 mutagenesis screens. These studies determined the function of every possible missense or nonsense TP53 mutations and have shown increased cell proliferation.

October 01, 2018
Journal of Cell Biology.

CTD2 scientists demonstrated that the myoepithelial cells block luminal epithelial cell dispersal. This depends on the smooth muscle contractility and adhesion.

September 28, 2018
Nature Communications

Integration of functional proteomics, systems biology, and molecular biology studies identified mTORC1 functions as a mediator between nutrition availability sensing and determinant for G2/M checkpoint recovery.

September 04, 2018
Scientific Reports

High-throughput functional siRNA screening in ovarian cancer cell lines identified that tyrosine kinase with immunoglobulin-like and EGF-like domains 1, TIE-1 confers resistance to cisplatin and could be a potential therapeutic target for platinum resistant ovarian cancer. 

September 01, 2018
Leukemia

Studies conducted by CTD2 scientists at Oregon Health and Science University have shown that combined inhibition of JAK1/2 and BCL2 as a potential therapeutic option for acute myeloid leukemia (AML) patients.

August 13, 2018
Nature Cell Biology

CTD2 researchers at UCSF showed that SHP2, a non-receptor protein tyrosine phosphatase, could be a potential molecular target in cancers driven by oncogenic mutants of RAS/MAPK pathway.

August 13, 2018
Journal of Clinical Pathology

Review on the role of CDK12 as a clinical biomarker and as a potential therapeutic target for cancer therapy.

Pages

CSV

.